Message #11 From:
NewsBot Date: October 19, 2005 08:30:00 PM
XNOM News Web Alert: Xenomics' Breakthrough DNA Technology to be Presented Today at Bio InvestorForum with Online Simulcast; CEO to Detail Revolutionary DNA Testing Technology Designed to Provide Noninvasive Diagnosis for Major Diseases
NEW YORK--(BUSINESS WIRE)--Oct. 20, 2005--Xenomics, Inc. (OTCBB: XNOM) (FSE: XE7), a developer of next-generation medical DNA technologies, announced that CEO Dr. Randy White will present its breakthrough proprietary Transrenal-DNA technology platform for noninvasive detection and monitoring of a range of diseases and genetic conditions, at the Bio InvestorForum 2005 today at 7 a.m. Eastern. The presentation will be webcast simultaneously online for viewing by interested investors.
What: Online simulcast of scientific and corporate overview
given by Xenomics CEO at Bio InvestorForum 2005.
Who: Dr. Randy White, CEO of Xenomics.
When: Today, 7 a.m. Eastern. (10 a.m. Pacific)
How: Visit http://becif.bio.org/opencms/bif/2005/index.jsp.
Select the "Conference Webcasting" option on the right
side of the page, and find Xenomics on the agenda for
the Oct. 20 presentations.
Dr. White will provide a corporate overview and highlights of Xenomics' proprietary Transrenal-DNA (Tr-DNA) technology, a potentially revolutionary medical diagnostic technology, which has broad applications for monitoring and/or detection of diseases and conditions including HIV, Tuberculosis (TB), as well as fetal genetic abnormalities such as Down syndrome. Xenomics' diagnostic technology is based on the noninvasive sampling of DNA material that passes through the kidneys, and is excreted in urine. This completely safe and accurate medical testing method could provide a feasible and affordable alternative to more invasive methods currently in use.
About Bio InvestorForum 2005
Bio InvestorForum 2005, "Showcasing the Leading Growth Companies in Life Sciences," is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" in 2006. This Forum will deliver a rich program featuring corporate presentations and panel debates on the sweet spots and growth challenges facing the industry, with more than 190 public and venture-stage company presentations included. For more information, please visit: http://becif.bio.org/opencms/bif/2005/index.jsp.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company's prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
